Share on StockTwits

Repros Therapeutics (NASDAQ:RPRX) CFO Katherine Anderson purchased 2,000 shares of Repros Therapeutics stock in a transaction that occurred on Thursday, August 14th. The shares were purchased at an average cost of $13.85 per share, for a total transaction of $27,700.00. Following the completion of the acquisition, the chief financial officer now directly owns 8,375 shares of the company’s stock, valued at approximately $115,994. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Repros Therapeutics (NASDAQ:RPRX) traded up 1.31% during mid-day trading on Thursday, hitting $13.94. The stock had a trading volume of 242,075 shares. Repros Therapeutics has a 52 week low of $12.61 and a 52 week high of $29.79. The stock’s 50-day moving average is $15.28 and its 200-day moving average is $16.87. The company’s market cap is $322.0 million.

Repros Therapeutics (NASDAQ:RPRX) last announced its earnings results on Monday, August 11th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by $0.01. Analysts expect that Repros Therapeutics will post $-1.53 EPS for the current fiscal year.

Repros Therapeutics, Inc is a United States-based company that develops products and services for the management of reproductive health.

Receive News & Ratings for Repros Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.